Drugs / CC-99712
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04036461 | Aug 2019 → Jul 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-99712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04036461 ↗ |
| Route | Intravenous | “CC-99712 will be administered via intravenous (IV) infusion.” NCT04036461 ↗ |